Recently, a French biotech company called Horama has signed an exclusive license agreement with Leiden University Medical Center targeting CRB1 gene mutations to treat inherited retinal dystrophies, which is expected to initiate a phase I/II clinical study with the drug candidate in 2023 (41). This evidence concerns the gene CRB1 and inherited retinal dystrophy.